OBJECTIVES: The HeartMate 3 left ventricular assist device was first implanted in 2014 and received the Conformité Européenne mark in 2015. Since then, several trials demonstrated its high haemocompatibility associated with good survival and low adverse events rates. Herein, we report our institutional experience with patients supported with HeartMate 3 for 5 years. METHODS: This prospective cohort study included patients receiving a HeartMate 3 implantation in 2014 as part of the HeartMate 3 Conformité Européenne Mark clinical trial. Patients had follow-up visits every 3 months while on left ventricular assist device support, and all patients completed the 5-year follow-up. The primary end point was survival at 5 years. Secondary end points included adverse events, health status and quality of life. RESULTS: Eight patients (men: 75%) aged 59 years (min-max: 52-66 years) were enrolled. At 5 years, survival was 100%. Patients remained on support for a median time of 1825 days (min-max: 101-1825 days); 2 patients successfully received cardiac transplants. No right heart failure, haemolysis, pump thrombosis, pump malfunction or neurological events occurred in any patients. A driveline infection was observed in 6 patients (0.25 events/patient-year). Compared to baseline, a significant improvement in quality of life and in New York Heart Association functional class was noted after the implant and for the whole follow-up time. A slight decline in kidney function and in the 6-min walk test results occurred after 3 years. CONCLUSIONS: This study reports the longest single-centre follow-up of the HeartMate 3, showing excellent haemocompatibility over time with high survival and low complication rates at 5 years.

Clinic for Thoracic and Cardiovascular Surgery Heart and Diabetes Center Bad Oeynhausen Germany

Department of Cardiology and Angiology Hannover Medical School Hannover Germany

Department of Cardiothoracic and Vascular Surgery German Heart Center Berlin Berlin Germany

Department of Cardiothoracic Surgery and Transplantation The Alfred Hospital and Monash University Melbourne Australia

Department of Cardiothoracic Transplantation and Vascular Surgery Hannover Medical School Hannover Germany

Department of Cardiovascular Surgery Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Cardiovascular Surgery Peter Munk Cardiac Centre Toronto General Hospital Toronto ON Canada

Department of Cardiovascular Surgery University Heart Center Freiburg and Medical Faculty of the Albert Ludwigs University Freiburg Freiburg Germany

Division of Cardiac Surgery Department of Surgery Medical University Vienna Vienna Austria

National Research Cardiac Surgery Center Nur Sultan Kazakhstan

University Department of Cardiac Surgery Heart Center Leipzig Leipzig Germany

Artif Organs. 2020 Dec;44(12):1310-1311. doi: 10.1111/aor.13774. PubMed

Eur J Cardiothorac Surg. 2021 Jun 14;59(6):1164-1165. doi: 10.1093/ejcts/ezab107. PubMed

Citace poskytuje Crossref.org